University of Maryland Greenebaum Cancer Center
🇺🇸United States
Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma
Phase 1
Completed
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- Biological: CMV pp65 peptideBiological: hTERT I540/R572Y/D988Y multipeptide vaccineBiological: pneumococcal polyvalent vaccineBiological: survivin Sur1M2 peptide vaccine
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- University of Maryland Greenebaum Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT00499577
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath